实验性阿尔茨海默氏病的药物GL-II-73在小鼠身上显示了希望,定于2025年进行人类试验。 Experimental Alzheimer's drug GL-II-73 shows promise in mice, set for human trials in 2025.

一种实验药物GL-II-73在改善患有阿尔茨海默氏病的老鼠的记忆和认知功能方面显示出前景。 An experimental drug, GL-II-73, has shown promise in improving memory and cognitive function in mice with Alzheimer's disease. 该药物由成瘾和精神健康中心(CAMH)的研究人员研制,针对脑部的GABA受体,扭转细胞损伤,为治疗阿尔茨海默氏病和其他认知障碍如抑郁症、癫痫和精神分裂症提供希望。 The drug, developed by researchers at the Centre for Addiction and Mental Health (CAMH), targets GABA receptors in the brain, reversing cell damage and offering hope for treating Alzheimer's and other cognitive impairments like depression, epilepsy, and schizophrenia. 该药物已得到林业发展局批准进行人类临床试验,第一阶段预计将于2025年初开始。 The drug has received FDA clearance for human clinical trials, with Phase 1 expected to begin in early 2025.